These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 16779730)

  • 41. Meningococcal Seroepidemiology 1 Year After the PsA-TT Mass Immunization Campaign in Burkina Faso.
    Tall H; Yaro S; Kpoda HB; Ouangraoua S; Trotter CL; Njanpop Lafourcade BM; Findlow H; Bai X; Martin C; Nwakamma I; Ouedraogo JB; Gessner BD; Borrow R; Mueller JE
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S540-6. PubMed ID: 26553686
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents.
    Baxter R; Reisinger K; Block SL; Izu A; Odrljin T; Dull P
    J Pediatr; 2014 Jun; 164(6):1409-15.e4. PubMed ID: 24657122
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase II meningococcal B vesicle vaccine trial in New Zealand infants.
    Jackson C; Lennon DR; Sotutu VT; Yan J; Stewart JM; Reid S; Crengle S; Oster P; Ypma E; Aaberge I; Mulholland K; Martin DR
    Arch Dis Child; 2009 Oct; 94(10):745-51. PubMed ID: 18838420
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study.
    Vesikari T; Forstén A; Desole MG; Ferrera G; Caubet M; Mesaros N; Boutriau D
    Pediatr Infect Dis J; 2013 May; 32(5):521-9. PubMed ID: 23190785
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
    Perrett KP; Snape MD; Ford KJ; John TM; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
    Pediatr Infect Dis J; 2009 Mar; 28(3):186-93. PubMed ID: 19209097
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serum group a anticapsular antibodies in a Sudanese population immunized with meningococcal polysaccharide vaccine during a group A epidemic.
    Ismail AA; Harris SL; Granoff DM
    Pediatr Infect Dis J; 2004 Aug; 23(8):748-55. PubMed ID: 15295225
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine.
    Dbaibo G; Van der Wielen M; Reda M; Medlej F; Tabet C; Boutriau D; Sumbul A; Anis S; Miller JM
    Int J Infect Dis; 2012 Aug; 16(8):e608-15. PubMed ID: 22704725
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expanding prevention of invasive meningococcal disease.
    Pelton SI; Gilmet GP
    Expert Rev Vaccines; 2009 Jun; 8(6):717-27. PubMed ID: 19485753
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine.
    El Bashir H; Heath PT; Papa T; Ruggeberg JU; Johnson N; Sinha R; Balfour G; Booy R
    Vaccine; 2006 Mar; 24(14):2544-9. PubMed ID: 16417952
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity.
    Welsch JA; Granoff D
    Infect Immun; 2004 Oct; 72(10):5903-9. PubMed ID: 15385492
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immediate and longer term immunogenicity of a single dose of the combined haemophilus influenzae type B-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in primed toddlers 12 to 18 months of age.
    Booy R; Richmond P; Nolan T; McVernon J; Marshall H; Nissen M; Reynolds G; Ziegler JB; Heron L; Lambert S; Caubet M; Mesaros N; Boutriau D
    Pediatr Infect Dis J; 2011 Apr; 30(4):340-2. PubMed ID: 21068692
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunogenicity of a meningococcal serogroup C conjugate vaccine in HIV-infected children, adolescents, and young adults.
    Bertolini DV; Costa LS; van der Heijden IM; Sato HK; Marques HH
    Vaccine; 2012 Aug; 30(37):5482-6. PubMed ID: 22771509
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunogenicity and safety of a booster dose of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine coadministered with the tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers: a randomized trial.
    Ruiz-Palacios GM; Huang LM; Lin TY; Hernandez L; Guerrero ML; Villalobos AL; Van der Wielen M; Moreira M; Fissette L; Borys D; Miller JM
    Pediatr Infect Dis J; 2013 Jan; 32(1):62-71. PubMed ID: 23076383
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Response of steroid-treated former preterm infants to a single dose of meningococcal C conjugate vaccine.
    Clarke P; Robinson MJ; Ahmad I; Bedford-Russell AR; Connell JE; Powell PJ; Heath PT
    Vaccine; 2006 Apr; 24(16):3273-8. PubMed ID: 16472548
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevention of meningococcal serogroup C disease by NeisVac-C.
    Borrow R; Findlow J
    Expert Rev Vaccines; 2009 Mar; 8(3):265-79. PubMed ID: 19249967
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Optimizing protection against meningococcal disease.
    Reisinger KS; Black S; Stoddard JJ
    Clin Pediatr (Phila); 2010 Jun; 49(6):586-97. PubMed ID: 20089551
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomized Trial to Compare the Immunogenicity and Safety of a CRM or TT Conjugated Quadrivalent Meningococcal Vaccine in Teenagers who Received a CRM or TT Conjugated Serogroup C Vaccine at Preschool Age.
    Ishola DA; Andrews N; Waight P; Yung CF; Southern J; Bai X; Findlow H; Matheson M; England A; Hallis B; Findlow J; Borrow R; Miller E
    Pediatr Infect Dis J; 2015 Aug; 34(8):865-74. PubMed ID: 26075813
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term protection in children with meningococcal C conjugate vaccination: lessons learned.
    Borrow R; Miller E
    Expert Rev Vaccines; 2006 Dec; 5(6):851-7. PubMed ID: 17184222
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Absence of Neisseria meningitidis serogroup C-specific antibodies during the first year of life in the Netherlands: an age group at risk?
    de Voer RM; van der Klis FR; Niers LE; Rijkers GT; Berbers GA
    Clin Vaccine Immunol; 2009 Oct; 16(10):1521-3. PubMed ID: 19692627
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A case of meningococcal disease in a schoolgirl previously given meningococcal C vaccine.
    Pugh RN; Heseltine A
    Commun Dis Public Health; 2002 Mar; 5(1):74. PubMed ID: 12070983
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.